Jeremy Grantham Jounce Therapeutics, Inc. Call Options Transaction History
Grantham, Mayo, Van Otterloo & Co. LLC
- $29.8 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding JNCE
# of Institutions
4Shares Held
720KCall Options Held
0Put Options Held
0About Jounce Therapeutics, Inc.
- Ticker JNCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,694,200
- Description
- Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...